<p>哈德遜灣資本管理公司在最近向美國證券交易委員會提交的 13F 文件中披露，第二季度將其在 Ionis Pharmaceuticals, Inc.（納斯達克代碼：IONS - 免費報告）中的持股比例降低了 28.6%。該基金在此期間出售了 299,900 股後，持有 750,000 股該公司的股票。截至其最近的 SEC 文件，哈德遜灣資本管理公司持有 Ionis Pharmaceuticals 約 0.47% 的股份，價值 29,632,000 美元。</p>
<p>獲取 <strong>Ionis Pharmaceuticals</strong> 的提醒：</p>
<ul>
<li>這 5 只被低估的股票準備突破嗎？</li>
</ul>
<p>其他幾家機構投資者和對沖基金最近也調整了對 IONS 的持股。T. Rowe Price Investment Management Inc.在第一季度將其在 Ionis Pharmaceuticals 的持股提高了 14.2%。T. Rowe Price Investment Management Inc.目前持有 16,175,533 股該公司的股票，價值 488,016,000 美元，在上個季度又購買了 2,006,334 股。Adage Capital Partners GP L.L.C.在第二季度將其在 Ionis Pharmaceuticals 的持股提高了 253.3%。Adage Capital Partners GP L.L.C.目前持有 3,800,000 股該公司的股票，價值 150,138,000 美元，在上個季度又購買了 2,724,400 股。Geode Capital Management LLC 在第二季度將其在 Ionis Pharmaceuticals 的持股提高了 1.7%。Geode Capital Management LLC 目前持有 2,891,095 股該公司的股票，價值 114,245,000 美元，在上個季度又收購了 48,141 股。BVF Inc. IL 在第一季度購買了 Ionis Pharmaceuticals 的新頭寸，價值 57,727,000 美元。最後，Groupama Asset Managment 在第二季度將其在 Ionis Pharmaceuticals 的持股提高了 8.6%。Groupama Asset Managment 目前持有 1,160,957 股該公司的股票，價值 45,869,000 美元，在上個季度又收購了 91,746 股。93.86% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Ionis Pharmaceuticals 的內部買賣</h2>
<p>在其他消息中，執行副總裁 Richard S. Geary 於 11 月 6 日（星期四）出售了 33,038 股 Ionis Pharmaceuticals 的股票。股票以平均價格 75.72 美元出售，總價值為 2,501,637.36 美元。交易完成後，該執行副總裁持有 59,657 股公司股票，價值 4,517,228.04 美元。這筆交易代表其持股比例減少了 35.64%。該交易已在向證券交易委員會提交的文件中披露，相關文件可在 SEC 網站上查閲。此外，董事 Joseph H. Wender 於 12 月 1 日（星期一）出售了 28,000 股公司的股票。股票以平均價格 80.82 美元出售，總交易額為 2,262,960.00 美元。交易完成後，該董事直接持有 36,035 股公司股票，價值約 2,912,348.70 美元。這筆交易代表其持股比例減少了 43.73%。該銷售的披露信息可在 SEC 文件中找到。在過去三個月中，內部人士出售了 504,866 股公司股票，價值 35,744,766 美元。公司內部人士持有 2.60% 的股票。</p>
<h2>Ionis Pharmaceuticals 的價格表現</h2>
<p>納斯達克 IONS 的股票在週五開盤價為 80.82 美元。該公司的流動比率為 2.79，速動比率為 2.78，債務與股本比率為 0.96。該股票的 50 日簡單移動平均為 74.91 美元，200 日簡單移動平均為 56.18 美元。Ionis Pharmaceuticals, Inc.的 1 年最低價為 23.95 美元，1 年最高價為 83.61 美元。該公司的市值為 130.9 億美元，市盈率為-47.82，貝塔值為 0.30。</p>
<p>Ionis Pharmaceuticals（納斯達克代碼：IONS - 獲取免費報告）最近在 10 月 29 日（星期三）發佈了季度財報。該公司報告季度每股收益（EPS）為-0.80 美元，超出分析師一致預期的-1.15 美元，超出幅度為 0.35 美元。該公司本季度的收入為 1.5672 億美元，而分析師預期為 1.3175 億美元。Ionis Pharmaceuticals 的股本回報率為-44.26%，淨利潤率為-26.45%。該公司本季度的收入較去年同期增長了 17.2%。在去年同期，該公司每股收益為-0.95 美元。分析師預計 Ionis Pharmaceuticals, Inc.在本年度的每股收益將為-3.5 美元。</p>
<h2>華爾街分析師的看法</h2>
<p>一些研究分析師最近對該股票發表了看法。Guggenheim 在 9 月 23 日（星期二）的研究報告中將 Ionis Pharmaceuticals 的目標股價從 90.00 美元上調至 92.00 美元，並給予該公司 “買入” 評級。美國銀行在 12 月 9 日（星期二）的研究報告中將 Ionis Pharmaceuticals 的目標股價從 86.00 美元上調至 97.00 美元，並給予該股票 “買入” 評級。摩根士丹利在 10 月 30 日（星期四）的報告中將 Ionis Pharmaceuticals 的目標股價從 90.00 美元上調至 94.00 美元，並給予該公司 “增持” 評級。Needham &amp; Company LLC 在 10 月 30 日（星期四）的報告中將 Ionis Pharmaceuticals 的目標股價從 78.00 美元上調至 90.00 美元，並給予該股票 “買入” 評級。最後，巴克萊在 10 月 30 日（星期四）的研究報告中將 Ionis Pharmaceuticals 的目標股價從 80.00 美元上調至 95.00 美元，並給予該股票 “增持” 評級。一位分析師對該股票給予了強烈買入評級，十七位分析師給予買入評級，三位分析師給予持有評級，一位分析師給予賣出評級。根據 MarketBeat.com 的數據，Ionis Pharmaceuticals 目前的共識評級為 “適度買入”，平均目標股價為 84.85 美元。</p>
<p><strong>查看我們關於 Ionis Pharmaceuticals 的最新報告</strong></p>
<h2>Ionis Pharmaceuticals 公司簡介</h2>
<p>（免費報告）</p>
<p>Ionis Pharmaceuticals, Inc. 在美國發現並開發針對 RNA 的治療藥物。該公司為兒童和成人患者提供用於脊髓性肌萎縮症 (SMA) 的 SPINRAZA；TEGSEDI，一種用於治療由遺傳性轉甲狀腺素澱粉樣變引起的多發性神經病的抗病毒注射劑；以及 WAYLIVRA，一種用於治療家族性乳糜微粒血癥 (FCS) 和家族性部分脂肪營養不良的抗病毒藥物。</p>
<h2>另見</h2>
<ul>
<li>五隻我們認為比 Ionis Pharmaceuticals 更好的股票</li>
<li>投資中的降級是什麼意思？</li>
<li>迪士尼與 OpenAI 達成 10 億美元交易，帶來魔力</li>
<li>WallStreetBets 是什麼，它們針對哪些股票？</li>
<li>為什麼亞馬遜可能在幾周內成為 300 美元的股票</li>
<li>S&amp;P/TSX 指數是什麼？</li>
<li>Adobe 在財報後獲得提振：長期前景看漲</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU9OUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU9OUw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Ionis Pharmaceuticals 嗎？</h2>
<p>在考慮 Ionis Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Ionis Pharmaceuticals 並不在名單上。</p>
<p>雖然 Ionis Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Ionis制藥

普信金融

<p>哈德遜灣資本管理公司在第二季度減少了對 Ionis 製藥的持股比例，降幅為 28.6%，目前持有價值 2963 萬美元的股份。其他投資者如普信金融和 Adage Capital 則增加了他們的持股。Ionis 報告第三季度收入增長 17.2%，虧損小於預期。分析師們提高了價格目標，古根海姆和美國銀行給予了積極的評級</p>

<p>Hudson Bay Capital Management LP lowered its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 28.6% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 750,000 shares of the company's stock after selling 299,900 shares during the period. Hudson Bay Capital Management LP owned approximately 0.47% of Ionis Pharmaceuticals worth $29,632,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>哈德遜灣資本管理公司在最近向美國證券交易委員會提交的 13F 文件中披露，第二季度將其在 Ionis Pharmaceuticals, Inc.（納斯達克代碼：IONS - 免費報告）中的持股比例降低了 28.6%。該基金在此期間出售了 299,900 股後，持有 750,000 股該公司的股票。截至其最近的 SEC 文件，哈德遜灣資本管理公司持有 Ionis Pharmaceuticals 約 0.47% 的股份，價值 29,632,000 美元。</p>
</div><p>Get <strong>Ionis Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Ionis Pharmaceuticals</strong> 的提醒：</p>
</div><ul>
<li>Are These 5 Undervalued Stocks Ready to Break Out?</li>
</ul>
<div class="lb-trans"><ul>
<li>這 5 只被低估的股票準備突破嗎？</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also recently modified their holdings of IONS. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Ionis Pharmaceuticals by 14.2% in the first quarter. T. Rowe Price Investment Management Inc. now owns 16,175,533 shares of the company's stock valued at $488,016,000 after purchasing an additional 2,006,334 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its position in Ionis Pharmaceuticals by 253.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,800,000 shares of the company's stock valued at $150,138,000 after buying an additional 2,724,400 shares during the last quarter. Geode Capital Management LLC lifted its stake in Ionis Pharmaceuticals by 1.7% during the 2nd quarter. Geode Capital Management LLC now owns 2,891,095 shares of the company's stock valued at $114,245,000 after acquiring an additional 48,141 shares in the last quarter. BVF Inc. IL purchased a new position in Ionis Pharmaceuticals during the 1st quarter worth $57,727,000. Finally, Groupama Asset Managment grew its stake in shares of Ionis Pharmaceuticals by 8.6% in the 2nd quarter. Groupama Asset Managment now owns 1,160,957 shares of the company's stock worth $45,869,000 after acquiring an additional 91,746 shares in the last quarter. 93.86% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他幾家機構投資者和對沖基金最近也調整了對 IONS 的持股。T. Rowe Price Investment Management Inc.在第一季度將其在 Ionis Pharmaceuticals 的持股提高了 14.2%。T. Rowe Price Investment Management Inc.目前持有 16,175,533 股該公司的股票，價值 488,016,000 美元，在上個季度又購買了 2,006,334 股。Adage Capital Partners GP L.L.C.在第二季度將其在 Ionis Pharmaceuticals 的持股提高了 253.3%。Adage Capital Partners GP L.L.C.目前持有 3,800,000 股該公司的股票，價值 150,138,000 美元，在上個季度又購買了 2,724,400 股。Geode Capital Management LLC 在第二季度將其在 Ionis Pharmaceuticals 的持股提高了 1.7%。Geode Capital Management LLC 目前持有 2,891,095 股該公司的股票，價值 114,245,000 美元，在上個季度又收購了 48,141 股。BVF Inc. IL 在第一季度購買了 Ionis Pharmaceuticals 的新頭寸，價值 57,727,000 美元。最後，Groupama Asset Managment 在第二季度將其在 Ionis Pharmaceuticals 的持股提高了 8.6%。Groupama Asset Managment 目前持有 1,160,957 股該公司的股票，價值 45,869,000 美元，在上個季度又收購了 91,746 股。93.86% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Insider Buying and Selling at Ionis Pharmaceuticals</h2>
<div class="lb-trans"><h2>Ionis Pharmaceuticals 的內部買賣</h2>
</div><p>In other news, EVP Richard S. Geary sold 33,038 shares of Ionis Pharmaceuticals stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $75.72, for a total value of $2,501,637.36. Following the completion of the transaction, the executive vice president owned 59,657 shares in the company, valued at $4,517,228.04. This trade represents a 35.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, Director Joseph H. Wender sold 28,000 shares of the business's stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $80.82, for a total transaction of $2,262,960.00. Following the completion of the sale, the director directly owned 36,035 shares in the company, valued at approximately $2,912,348.70. This trade represents a 43.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 504,866 shares of company stock valued at $35,744,766 in the last three months. 2.60% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他消息中，執行副總裁 Richard S. Geary 於 11 月 6 日（星期四）出售了 33,038 股 Ionis Pharmaceuticals 的股票。股票以平均價格 75.72 美元出售，總價值為 2,501,637.36 美元。交易完成後，該執行副總裁持有 59,657 股公司股票，價值 4,517,228.04 美元。這筆交易代表其持股比例減少了 35.64%。該交易已在向證券交易委員會提交的文件中披露，相關文件可在 SEC 網站上查閲。此外，董事 Joseph H. Wender 於 12 月 1 日（星期一）出售了 28,000 股公司的股票。股票以平均價格 80.82 美元出售，總交易額為 2,262,960.00 美元。交易完成後，該董事直接持有 36,035 股公司股票，價值約 2,912,348.70 美元。這筆交易代表其持股比例減少了 43.73%。該銷售的披露信息可在 SEC 文件中找到。在過去三個月中，內部人士出售了 504,866 股公司股票，價值 35,744,766 美元。公司內部人士持有 2.60% 的股票。</p>
</div><h2>Ionis Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Ionis Pharmaceuticals 的價格表現</h2>
</div><p>Shares of NASDAQ IONS opened at $80.82 on Friday. The company has a current ratio of 2.79, a quick ratio of 2.78 and a debt-to-equity ratio of 0.96. The stock has a fifty day simple moving average of $74.91 and a two-hundred day simple moving average of $56.18. Ionis Pharmaceuticals, Inc. has a 1-year low of $23.95 and a 1-year high of $83.61. The firm has a market cap of $13.09 billion, a price-to-earnings ratio of -47.82 and a beta of 0.30.</p>
<div class="lb-trans"><p>納斯達克 IONS 的股票在週五開盤價為 80.82 美元。該公司的流動比率為 2.79，速動比率為 2.78，債務與股本比率為 0.96。該股票的 50 日簡單移動平均為 74.91 美元，200 日簡單移動平均為 56.18 美元。Ionis Pharmaceuticals, Inc.的 1 年最低價為 23.95 美元，1 年最高價為 83.61 美元。該公司的市值為 130.9 億美元，市盈率為-47.82，貝塔值為 0.30。</p>
</div><p>Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($1.15) by $0.35. The firm had revenue of $156.72 million for the quarter, compared to analysts' expectations of $131.75 million. Ionis Pharmaceuticals had a negative return on equity of 44.26% and a negative net margin of 26.45%.The business's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.95) EPS. Analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.</p>
<div class="lb-trans"><p>Ionis Pharmaceuticals（納斯達克代碼：IONS - 獲取免費報告）最近在 10 月 29 日（星期三）發佈了季度財報。該公司報告季度每股收益（EPS）為-0.80 美元，超出分析師一致預期的-1.15 美元，超出幅度為 0.35 美元。該公司本季度的收入為 1.5672 億美元，而分析師預期為 1.3175 億美元。Ionis Pharmaceuticals 的股本回報率為-44.26%，淨利潤率為-26.45%。該公司本季度的收入較去年同期增長了 17.2%。在去年同期，該公司每股收益為-0.95 美元。分析師預計 Ionis Pharmaceuticals, Inc.在本年度的每股收益將為-3.5 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師的看法</h2>
</div><p>A number of research analysts recently weighed in on the stock. Guggenheim raised their price target on shares of Ionis Pharmaceuticals from $90.00 to $92.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, September 23rd. Bank of America lifted their target price on shares of Ionis Pharmaceuticals from $86.00 to $97.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday, December 9th. Morgan Stanley upped their target price on Ionis Pharmaceuticals from $90.00 to $94.00 and gave the company an &#34;overweight&#34; rating in a report on Thursday, October 30th. Needham &amp; Company LLC lifted their price target on Ionis Pharmaceuticals from $78.00 to $90.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, October 30th. Finally, Barclays boosted their price objective on Ionis Pharmaceuticals from $80.00 to $95.00 and gave the stock an &#34;overweight&#34; rating in a research report on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Ionis Pharmaceuticals currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $84.85.</p>
<div class="lb-trans"><p>一些研究分析師最近對該股票發表了看法。Guggenheim 在 9 月 23 日（星期二）的研究報告中將 Ionis Pharmaceuticals 的目標股價從 90.00 美元上調至 92.00 美元，並給予該公司 “買入” 評級。美國銀行在 12 月 9 日（星期二）的研究報告中將 Ionis Pharmaceuticals 的目標股價從 86.00 美元上調至 97.00 美元，並給予該股票 “買入” 評級。摩根士丹利在 10 月 30 日（星期四）的報告中將 Ionis Pharmaceuticals 的目標股價從 90.00 美元上調至 94.00 美元，並給予該公司 “增持” 評級。Needham &amp; Company LLC 在 10 月 30 日（星期四）的報告中將 Ionis Pharmaceuticals 的目標股價從 78.00 美元上調至 90.00 美元，並給予該股票 “買入” 評級。最後，巴克萊在 10 月 30 日（星期四）的研究報告中將 Ionis Pharmaceuticals 的目標股價從 80.00 美元上調至 95.00 美元，並給予該股票 “增持” 評級。一位分析師對該股票給予了強烈買入評級，十七位分析師給予買入評級，三位分析師給予持有評級，一位分析師給予賣出評級。根據 MarketBeat.com 的數據，Ionis Pharmaceuticals 目前的共識評級為 “適度買入”，平均目標股價為 84.85 美元。</p>
</div><p><strong>Check Out Our Latest Report on Ionis Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Ionis Pharmaceuticals 的最新報告</strong></p>
</div><h2>Ionis Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Ionis Pharmaceuticals 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.</p>
<div class="lb-trans"><p>Ionis Pharmaceuticals, Inc. 在美國發現並開發針對 RNA 的治療藥物。該公司為兒童和成人患者提供用於脊髓性肌萎縮症 (SMA) 的 SPINRAZA；TEGSEDI，一種用於治療由遺傳性轉甲狀腺素澱粉樣變引起的多發性神經病的抗病毒注射劑；以及 WAYLIVRA，一種用於治療家族性乳糜微粒血癥 (FCS) 和家族性部分脂肪營養不良的抗病毒藥物。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Ionis Pharmaceuticals</li>
<li>What Does Downgrade Mean in Investing?</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
<li>What Is WallStreetBets and What Stocks Are They Targeting?</li>
<li>Why Amazon Could Be a $300 Stock Within Weeks</li>
<li>What is the S&amp;P/TSX Index?</li>
<li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Ionis Pharmaceuticals 更好的股票</li>
<li>投資中的降級是什麼意思？</li>
<li>迪士尼與 OpenAI 達成 10 億美元交易，帶來魔力</li>
<li>WallStreetBets 是什麼，它們針對哪些股票？</li>
<li>為什麼亞馬遜可能在幾周內成為 300 美元的股票</li>
<li>S&amp;P/TSX 指數是什麼？</li>
<li>Adobe 在財報後獲得提振：長期前景看漲</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU9OUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=IONS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Ionis Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Ionis Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Ionis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Ionis Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ionis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Ionis Pharmaceuticals 並不在名單上。</p>
</div><p>While Ionis Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Ionis Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Hudson Bay Capital Management LP 持有 Ionis 製藥公司價值 2963 萬美元的股份